#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?
Nov 15, 2021
In an engaging AMA, the discussion dives into GLP-1 agonists and their emerging role in treating obesity. The hosts explore the exciting discovery of these peptides and their physiological impact. Highlighting a groundbreaking study, they share remarkable weight loss results from semaglutide injections. Additionally, they compare these findings to various lifestyle interventions, scrutinizing their effectiveness. The dialogue is filled with insights into the incretin effect and the future potential of these innovative drugs.
14:19
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
GLP-1 Agonists for Obesity
GLP-1 agonists treat obesity and are gaining popularity.
Semaglutide, also known as Ozempic, showed remarkable weight loss results in a recent study.
insights INSIGHT
Incretin Effect Explained
Insulin and glucagon are key hormones to understand how incretins work.
The incretin effect is a mismatch between how oral and intravenous glucose is processed.
insights INSIGHT
Oral vs. Intravenous Glucose
Oral glucose leads to a greater insulin response than intravenous glucose.
This difference, known as the incretin effect, also impacts glucagon levels.
Get the Snipd Podcast app to discover more snips from this episode
In this “Ask Me Anything” (AMA) episode, Peter and Bob discuss all things related to GLP-1 agonists—a class of drugs that are gaining popularity for the treatment of obesity. They cover the discovery of these peptides, their physiology, and what it is they do in their natural state. Next, Peter and Bob break down a recently published study which showed remarkable results for weight loss and other metabolic parameters using a once-weekly injection of the GLP-1 agonist drug semaglutide, also known as Ozempic, in overweight and obese patients. Finally, they compare results from the semaglutide study to results from various lifestyle interventions and give their take on the potential future of GLP-1 agonists. If you’re not a subscriber and listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or on our website at the AMA #29 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:
Remarkable results of a recent study in overweight adults [2:15];
Key background on insulin, glucagon and the incretin effect [4:00];
What is GLP-1 and how does it work? [16:30];
2021 semaglutide study: remarkable results, side effects, and open questions [30:00];
Semaglutide vs. lifestyle interventions: comparing results with semaglutide vs. lifestyle interventions alone [44:00];
Closing thoughts and open questions on the therapeutic potential of semaglutide [47:30]; and
The Peter Attia Drive